STI-1386
- Generic Name
- STI-1386
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- CancerSarcomaCancer of PancreasHepatic MetastasisSolid Tumor
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05361954
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath